PURPOSE: To compare rates of myopia progression and adverse events between orthokeratology (OK) and soft contact lens (SCL) wearers over a 10-year period in schoolchildren. METHODS: Medical records of consecutive patients (≤16 years of age at baseline) who started OK for myopia correction and continued the treatment for 10 years were retrospectively reviewed. For the control group, patients who started using soft contact lenses (SCLs) for myopia correction and continued to use them for 10 years were also reviewed. Clinical data, including sex, age, manifest refraction, visual acuity, prescription lens power, and adverse events during the 10-year period, were recorded. Estimated myopia progression was calculated as the sum of 'changes in prescription lens power during 10 years' and 'residual refractive errors at the 10-year visit,' and was compared between groups. We also compared the incidence of adverse events between groups over the 10-year study period. RESULTS: A total of 104 eyes of 53 patients who underwent OK treatment and 78 eyes of 39 patients who wore SCLs fulfilled the criteria. The estimated myopia progression over the 10-year period found in the OK and SCL groups were -1.26 ± 0.98 and -1.79 ± 1.24 days, respectively; this difference was statistically significant (p = 0.001). Additionally, lower myopia progression was found in the OK in comparison to the SCL group at all baseline ages (p = 0.003 to p = 0.049) except at 16 years old (p = 0.41). No significant difference was found in the number of adverse events found between the OK (119) and SCL (103) groups (p = 0.72). CONCLUSIONS: The results of this study supports the long-term efficacy and safety of OK lens wear in reducing myopia progression in schoolchildren.
PURPOSE: To compare rates of myopia progression and adverse events between orthokeratology (OK) and soft contact lens (SCL) wearers over a 10-year period in schoolchildren. METHODS: Medical records of consecutive patients (≤16 years of age at baseline) who started OK for myopia correction and continued the treatment for 10 years were retrospectively reviewed. For the control group, patients who started using soft contact lenses (SCLs) for myopia correction and continued to use them for 10 years were also reviewed. Clinical data, including sex, age, manifest refraction, visual acuity, prescription lens power, and adverse events during the 10-year period, were recorded. Estimated myopia progression was calculated as the sum of 'changes in prescription lens power during 10 years' and 'residual refractive errors at the 10-year visit,' and was compared between groups. We also compared the incidence of adverse events between groups over the 10-year study period. RESULTS: A total of 104 eyes of 53 patients who underwent OK treatment and 78 eyes of 39 patients who wore SCLs fulfilled the criteria. The estimated myopia progression over the 10-year period found in the OK and SCL groups were -1.26 ± 0.98 and -1.79 ± 1.24 days, respectively; this difference was statistically significant (p = 0.001). Additionally, lower myopia progression was found in the OK in comparison to the SCL group at all baseline ages (p = 0.003 to p = 0.049) except at 16 years old (p = 0.41). No significant difference was found in the number of adverse events found between the OK (119) and SCL (103) groups (p = 0.72). CONCLUSIONS: The results of this study supports the long-term efficacy and safety of OK lens wear in reducing myopia progression in schoolchildren.
Authors: Meng-Jun Zhu; Li Ding; Lin-Lin Du; Jun Chen; Xian-Gui He; Shan-Shan Li; Hai-Dong Zou Journal: Int J Ophthalmol Date: 2022-08-18 Impact factor: 1.645
Authors: Ying Zhu; Jing Fang Bian; Da Qian Lu; Chi Ho To; Carly Siu-Yin Lam; King Kit Li; Feng Juan Yu; Bo Teng Gong; Qiong Wang; Xiao Wen Ji; Hong Mei Zhang; Hong Nian; Thomas Chuen Lam; Rui Hua Wei Journal: Front Pharmacol Date: 2022-01-28 Impact factor: 5.810
Authors: Weiwei Lu; Rui Ning; Kai Diao; Yang Ding; Ruru Chen; Lei Zhou; Yan Lian; Colm McAlinden; Francis W B Sanders; Fangfang Xia; Jinhai Huang; Wanqing Jin Journal: Front Med (Lausanne) Date: 2022-04-01